MARKET

CELU

CELU

Celularity Inc
NASDAQ
3.020
-0.050
-1.63%
After Hours: 2.910 -0.11 -3.64% 19:25 04/26 EDT
OPEN
3.080
PREV CLOSE
3.070
HIGH
3.360
LOW
2.895
VOLUME
49.51K
TURNOVER
0
52 WEEK HIGH
8.90
52 WEEK LOW
1.590
MARKET CAP
65.78M
P/E (TTM)
-0.2874
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CELU last week (0415-0419)?
Weekly Report · 4d ago
Celularity receives Nasdaq notice regarding late Form 10-K filing
Seeking Alpha · 04/19 21:33
Celularity Inc: Statement of changes in beneficial ownership of securities
Press release · 04/17 02:09
Celularity Says That Its Expected Net Sales For Q1 2024 Are Trending Ahead Of The Expectations It Announced In February For Its Advanced Biomaterial Products And Biobanking Businesses; Implements Planned 2024 SG&A Reductions And Manufacturing Ramp For Advanced Biomaterial Products
Expects the First Quarter of 2024 will be the 4th consecutive quarter of both sequential and quarter-on-quarter net sales growth. Celularity's expected net sales for the first quarter of 2024 are trending ahead of the expectations it announced in February. Company developing placental-derived allogeneic cell therapies and advanced biomaterial products. Plan to reduce 2024 selling, general & administrative expenses and executive cash compensation.
Benzinga · 04/15 12:15
Weekly Report: what happened at CELU last week (0408-0412)?
Weekly Report · 04/15 09:47
Celularity To Present Data Showing Senescent Cell Elimination By Off-The-Shelf Natural Killer Cells Derived From Human Placental Cells
Celularity Inc. Will present in vitro data from its placenta-derived natural killer cell therapy programs at the American Society of Gene and Cell Therapy Annual Meeting in May 2024. Celularity is a biotechnology company developing cell therapies to address age-related diseases. Senescent cells are key drivers in the process of degenerative diseases and cancer.
Benzinga · 04/08 13:03
Weekly Report: what happened at CELU last week (0401-0405)?
Weekly Report · 04/08 09:48
Weekly Report: what happened at CELU last week (0325-0329)?
Weekly Report · 04/01 09:48
More
About CELU
Celularity Inc. is a clinical-stage biotechnology company. The Company is engaged in developing off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include T cells engineered with a chimeric antigen receptor (CAR), natural killer, cells, mesenchymal-like adherent stromal cells (MLASCs), and exosomes. These therapeutic candidates target indications across cancer, infectious and degenerative diseases. Its cell therapeutic programs include CYCART-19, CYCART-201, CYNK-001, CYNK-301, CYNK-302, APPL-001, and pEXO-001. CYCART-19 is a placental-derived CAR-T cell therapy, in development for the treatment of B-cell malignancies, initially targeting the cluster of differentiation 19. pExo-001 is developed for the treatment of osteoarthritis. APPL-001 is developed for the treatment of Crohn’s disease.

Webull offers Celularity Inc stock information, including NASDAQ: CELU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CELU stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CELU stock methods without spending real money on the virtual paper trading platform.